These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21328814)

  • 1. FDA notifications. Entecavir (Baraclude®) labeling changed.
    AIDS Alert; 2010 Dec; 25(12):141-2. PubMed ID: 21328814
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA notifications. FDA revises Baraclude labeling for HIV patients.
    AIDS Alert; 2007 Sep; 22(9):103-4. PubMed ID: 18415955
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA notifications. Entecavir is approved for chronic hepatitis B infection in adults.
    AIDS Alert; 2005 Jul; 20(7):83-4. PubMed ID: 16114113
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA notifications. Entecavir revision made by FDA and BMS.
    AIDS Alert; 2007 Apr; 22(4):43. PubMed ID: 17595722
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA, Bristol-Myers Squibb issue warning on hepatitis B drug.
    AIDS Read; 2007 Oct; 17(10):478-510. PubMed ID: 17987701
    [No Abstract]   [Full Text] [Related]  

  • 6. Entecavir (Baraclude°) and chronic hepatitis B in children.
    Prescrire Int; 2017 Feb; 26(179):42-43. PubMed ID: 30726630
    [No Abstract]   [Full Text] [Related]  

  • 7. Entecavir (Baraclude) for chronic hepatitis B.
    Med Lett Drugs Ther; 2005 Jun; 47(1210):47-8. PubMed ID: 15933618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir for chronic hepatitis B: a review.
    Palumbo E
    Ther Drug Monit; 2008 Feb; 30(1):1-4. PubMed ID: 18223455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
    Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
    N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing landscape of antiviral resistance management in chronic hepatitis B.
    Nguyen T; Locarnini S; Desmond P
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.
    de Man RA; Wolters LM; Nevens F; Chua D; Sherman M; Lai CL; Gadano A; Lee Y; Mazzotta F; Thomas N; DeHertogh D
    Hepatology; 2001 Sep; 34(3):578-82. PubMed ID: 11526545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Entecavir. Treatment of chronic hepatitis b virus infections].
    Musch A
    Med Monatsschr Pharm; 2006 Nov; 29(11):392-6. PubMed ID: 17131685
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?
    Zoulim F
    Hepatology; 2006 Dec; 44(6):1404-7. PubMed ID: 17133478
    [No Abstract]   [Full Text] [Related]  

  • 16. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Entecavir].
    Kobashi H
    Nihon Rinsho; 2011 May; 69 Suppl 4():486-91. PubMed ID: 22096966
    [No Abstract]   [Full Text] [Related]  

  • 18. Focus.
    Shouval D
    J Hepatol; 2011 Feb; 54(2):189-90. PubMed ID: 21087807
    [No Abstract]   [Full Text] [Related]  

  • 19. Entecavir: new drug. Chronic hepatitis B: a last resort.
    Prescrire Int; 2007 Oct; 16(91):183-5. PubMed ID: 17926822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA notifications. New treatment approved for chronic hepatitis B.
    AIDS Alert; 2002 Nov; 17(11):146-7. PubMed ID: 12412570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.